All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, What are the highlights of the ESH 8th Translational Research Conference: Myelodysplastic Syndromes?
Highlights of the 8th Translational Research Conference: Myelodysplastic Syndromes
De Witte begins by discussing new molecular MDS-specific mutations and how they can impact diagnosis and prognosis. De Witte goes on to define the pre-stages of MDS and myeloproliferative neoplasms (MPN), in particular clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenia of undetermined significance (CCUS).
Editorial theme | Immune dysregulation and genetic mutations associated with MDS pathogenesis
The pathogenesis of myelodysplastic syndromes (MDS) is heterogeneous, involving inflammation, cytokines, growth factors, the accumulation of genetic damage,...
What are the challenges in diagnosing MDS?
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub spoke to Aziz Nazha, Cleveland Clinic, Cleveland, US. We asked: What are the challenges in diagnosing MDS?
Subscribe to get the best content related to MDS delivered to your inbox